# US 10,478,440 B2 · Pharmaceutical compositions for inhibiting angiogenesis comprising plant-derived natural compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,478,440 B2
- Document ID: US10478440B2
- Status: Granted
- Kind: B2
- Application number: 15/591,709
- Filed: 2017-05-10
- Published: 2017-08-24
- Granted: 2019-11-19
- Earliest claimed: 2011-11-28
- Assignees: Industry-Academic Cooperation Foundation, Yonsei University
- Applicants: Industry-Academic Cooperation Foundation, Yonsei University
- Inventors: Ho Jeong Kwon; Yong Hyo Kim
- Web page: https://patentgrep.com/patent/US10478440B2

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a pharmaceutical composition for inhibiting angiogenesis containing a plant-derived natural compound which can be effective for preventing or treating disorders or diseases associated with angiogenesis. The compound used as an active ingredient in the pharmaceutical composition of the present invention suppresses VEGF-induced angiogenic responses without cytotoxicity at a low concentration by inhibiting the expression of an anti-angiogenic factor (for example, VEGF), and thus remarkably improves the safety of a drug.

## Claims

### Claim 1

A method for treating cancer selected from the group consisting of lung cancer, breast cancer, pancreatic cancer, thyroid cancer, and glioblastoma the method comprising administering to a subject in need thereof, a composition comprising as an active ingredient a compound represented by Chemical Formula 1 below:
wherein, R1, R2, and R3 each are independently hydrogen, C1-12 alkyl, C1-12 alkoxy, hydroxy, CN, CONH2, halo, oxazolyl, C1-12 alkylthio, or trifluoro(C1-2) alkyl.

### Claim 2 (depends on 1)

The method of claim 1, wherein R1, R2, and R3 each are independently hydrogen, halo, or C1-12 alkyl.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is represented by Chemical Formula 2 below: